ARTICLE
Translational Therapeutics

Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment

Koji Takada1, Shinichiro Kashiwagi1, Wataru Goto1, Yuka Asano1, Katsuyuki Takahashi2, Takaharu Hatano3, Tsutomu Takashima1, Shuhei Tomita2, Hisashi Motomura1, Masahiko Ohsawa4, Kosei Hirakawa1 and Masaichi Ohira1

BACKGROUND: Immune responses in a tumour microenvironment can be evaluated by analysing tumour-infiltrating lymphocyte (TIL) density; this has been verified in the clinical setting. Although there are many reports on TIL density in primary tumours, little is known about its density in recurrent tumours.

METHODS: Of 300 patients treated with neoadjuvant chemotherapy during the study period, 29 were considered for evaluation of TIL density in primary and recurrent tumours. We performed a retrospective analysis of the association between TIL density and prognosis.

RESULTS: TIL density was significantly lower in recurrent tumours than in primary tumours ($P = 0.007$). There was no correlation between post-recurrence survival and TIL density in core-needle biopsy specimens obtained from primary tumours ($P = 0.837$). However, patients with high TIL density in recurrent tumours had significantly better post-recurrence survival than did the corresponding group with low TIL density ($P = 0.041$). Multivariate analysis revealed that high TIL density contributed significantly towards improving post-recurrence survival in all patients ($P = 0.035$; hazard ratio, 0.167).

CONCLUSIONS: In recurrent breast cancer, a decrease in TILs density was observed as compared to the primary tumour, and this affects the poor prognosis after relapse.

British Journal of Cancer (2018) 119:572–579; https://doi.org/10.1038/s41416-018-0197-4

INTRODUCTION
An evaluation of the expression of various hormonal receptors is an important component of decision-making for the treatment of breast cancer. However, expression of these receptors may change during treatment and during recurrence.1–4 Therefore, when recurrent tumours are diagnosed on histological examination of biopsy specimens, reconfirmation of oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor-2 (HER2) expression becomes critical.

The immune milieu within the tumour microenvironment (TME) is involved in many anti-tumour treatment effects. For patients with high-risk breast cancers, such as triple-negative breast cancer (TNBC) and HER2-enriched breast cancer (HER2BC), tumour-infiltrating lymphocytes (TILs) are a biomarker for monitoring therapeutic effects and for prognostication. Recently, subset analyses have been initiated to understand the role of TILs. In many studies, TILs are evaluated in pre-treatment specimens, and only clinicopathological features such as pathological complete response (pCR), disease-free survival, and overall survival are considered as end points.5 6 However, little is known about the role of TILs in breast cancer recurrence. Because of discordance in receptor status between primary and recurrent tumours, the TIL profile may vary after treatment; therefore, further evaluation could aid in understanding the role of TILs as a biomarker for treatment effects and prognosis.

We hypothesised that immune responses within the TME may be aggravated at the time of recurrence and may affect treatment of recurrent disease. In this study, we analysed the relationship between changes in TIL density following treatment and post-recurrence survival (PRS) in patients with histologically confirmed recurrence.

METHODS
Patient characteristics
A total of 300 patients with resectable, early-stage (stage IIA [T1, N1, M0 or T2, N0, M0], IIB [T2, N1, M0 or T3, N0, M0], or IIIA [T1–2, N2, M0 or T3, N1–2, M0]) breast cancer were treated with neoadjuvant chemotherapy between February 2007 and August 2016 at Osaka City University Hospital.7 Thirty-six cases were excluded because the initial pathological diagnosis was made at other hospitals; thus, we were unable to evaluate the pre-treatment TIL status of these patients. Recurrence was observed in 49 of the remaining 264 patients. However, 20 had distant metastases that were not biopsied; hence, 29 cases were examined (Fig. 1).

1Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan; 2Department of Pharmacology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan; 3Department of Plastic and Reconstructive Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan and 4Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan
Correspondence: Shinichiro Kashiwagi (spqv9ke9@view.ocn.ne.jp)

Received: 16 December 2017 Revised: 15 June 2018 Accepted: 2 July 2018
Published online: 23 July 2018

© Cancer Research UK 2018
Significance of re-biopsy for recurrent breast cancer in the immune...  
K Takada et al.

A total of 300 cases with resectable, early-stage breast cancer were treated with NAC between 2007 and 2016 $n=300$

Cases with pathological diagnosis only of primary tumour by biopsy at other hospital $n=36$

Post-operative recurrence cases $n=49$

Cases with no biopsy specimens due to distant metastasis recurrence $n=20$

Research subject case that can be evaluated for TILs of primary and recurrent tumour $n=29$

Fig. 1 CONSORT diagram. In total, 300 patients with resectable, early-stage breast cancer were treated with neoadjuvant chemotherapy from February 2007 until August 2016 at Osaka City University Hospital; 36 were excluded as the pathological diagnosis of the primary tumour was made at another hospital. Of 264 remaining patients, 49 cases of post-operative recurrence were observed; 20 were excluded due to non-availability of biopsy specimens due to distant metastasis recurrence.

TNM staging was based on the seventh edition of the American Committee on Cancer Staging Manual.8 Breast cancer was confirmed by histological examination of core needle or vacuum-assisted biopsy specimens. Staging was determined using systemic imaging studies, including computed tomography, ultrasonography, and bone scintigraphy. Breast cancer was classified into subtypes according to the immunohistochemical expression of ER, PgR, HER2, and Ki67. Based on their immunohistochemical expression profiles, tumours were categorised into the following immunophenotypes: luminal A (ER+ and/or PgR+, HER2−, Ki67-low); luminal B ([ER+ and/or PgR−, HER2+] or [ER+ and/or PgR+, HER2−, Ki67-high]); HER2BC (ER−, PgR−, HER2+); and TNBC (ER, PgR, and HER2−).

In this study, luminal A and luminal B types were classified as hormone receptor-positive breast cancer (HRBC).9 All patients received a standardised protocol of neoadjuvant chemotherapy comprising four courses of FEC100 (500 mg/m² fluorouracil, 100 mg/m² epirubicin, and 500 mg/m² cyclophosphamide) every 3 weeks, followed by 12 courses of 80 mg/m² paclitaxel administered weekly. In addition, patients with HER2BC received trastuzumab weekly (2 mg/kg) or tri-weekly (6 mg/kg) during paclitaxel treatment.10-12 All patients received chemotherapy on an outpatient basis. Therapeutic anti-tumour effects were assessed according to the Response Evaluation Criteria in Solid Tumours.13

Patients underwent mastectomy or breast-conserving surgery following neoadjuvant chemotherapy.14 The pathological effect of chemotherapy was assessed for resected primary tumours after neoadjuvant chemotherapy. The pCR was defined as the complete disappearance of the invasive components of the lesion with or without intraductal components, including that in the lymph nodes, according to the National Surgical Adjuvant Breast and Bowel Project B-18 protocol.15 All patients who underwent breast-conserving surgery received post-operative radiotherapy to the remnant breast. Standard post-operative adjuvant therapy was administered based on the subtype. PRS was defined as the time from recurrence to the date of death from any cause. Disease-free survival was defined as the time from surgery to local, locoregional, or distant recurrence, and overall survival was defined as the time from surgery to the date of death resulting from any cause. Progression-free survival was defined as the time from the date of treatment after recurrence to either the date of confirmation of progressive disease or the date of death (whichever came first). The variable clinical response was a composite of clinical partial response and clinical complete response, whereas the variable clinical non-response was a composite of clinical stable disease and clinical progressive disease; these variables were used to determine the objective response rate.

All patients underwent follow-up physical examination every 3 months, ultrasound every 6 months, and CT and bone scintigraphy annually. The median follow-up interval from the date of surgery was 210 (range, 10–497) weeks for all 264 cases, and was 195 (range, 35–484) weeks for the 29 patients with post-operative recurrence.

Ethics statement
This study was conducted at the Osaka City University Graduate School of Medicine, Osaka, Japan, according to the REporting recommendations for Tumour MARKer prognostic studies (REMARK) guidelines and a retrospectively written research, pathological evaluation, and statistical analysis plan.16 Written informed consent was obtained from all patients. This research adhered to the provisions of the Declaration of Helsinki, 2013. The Ethics Committee of Osaka City University approved the study protocol (Number: 926).

Histopathological evaluation of TIL density
Core needle or vacuum-assisted biopsy specimens and initial surgical specimens, obtained at the time of breast cancer diagnosis and recurrence, underwent histopathological assessment to determine TIL density; single haematoxylin and eosin-stained tumour sections were examined according to the criteria described by Salgado et al. TILs, defined as lymphocytes infiltrating the tumour stroma, were expressed in proportion to...
the field investigated; the number of TILs in the stroma surrounding stained cancer cells was quantitatively measured in each field under 400x magnification. Areas of in situ carcinoma and crush artefact were not included. Proportional scores were defined as 3, 2, 1, and 0 if lymphoplasmacytic infiltration of the stroma around the invasive tumour cell nests was >50%, 10–50%, ≤10%, and absent, respectively (Supplemental Fig. 1). The presence of TILs was considered positive when scores were ≥2 and negative when scores were 1 or 0. Two breast pathologists, blinded to clinical information including treatment allocation and outcomes, jointly performed the histopathological evaluation of TIL.

Statistical analysis
The statistical analyses were conducted using JMP software (SAS, Tokyo, Japan). The relationship between each factor was examined using the χ² test. The Kaplan–Meier method and the log-rank test were used for comparison between PRS and overall survival. The Cox proportional hazards model was used to compute univariate and multivariate hazard ratios (HRs) for the study parameters with 95% confidence intervals (CIs) and was used in a backward stepwise method for variate selection in multivariate analysis. A P-value <0.05 was considered significant.

RESULTS
Correlation between clinicopathological features and TIL density in primary and recurrent tumours
A total of 300 patients underwent surgery after neoadjuvant chemotherapy; however, in some cases, it was not possible to either evaluate biopsy specimens during diagnosis or perform a biopsy due to distant metastasis. Of the 300 patients, 29 had biopsies performed for recurrent tumours during the post-operative follow-up period (Table 1). All 29 patients were women, with a median age of 53 (30–69) years. Regarding intrinsic subtypes, 11 (37.9%) cases were HRBC, seven (24.2%) were HER2BC, and 11 (37.9%) were TNBC. At initial diagnosis, 15 (51.7%) cases had high TIL density and 14 (48.3%) had low TIL density. Following neoadjuvant chemotherapy, the clinical response and pCR rates were 75.9% and 24.1%, respectively. Regarding adjuvant therapy, 12 (41.4%) patients received hormonal therapy, 14 (48.3%) received radiation therapy, seven (24.1%) received trastuzumab, and five (17.2%) were untreated. The median disease-free survival interval was 65 weeks, and local recurrence was observed in 18 (62.1%) cases; one patient had concurrent bone metastasis.

Of the 264 patients treated with neoadjuvant chemotherapy, 124 had high TIL density (Supplemental Table 1). Expression of ER (±0.001) and PgR (P < 0.001) was significantly lower in the high-TIL group than in the low-TIL group; HER2 expression was significantly higher (P = 0.001). Thus, TIL density was significantly higher in patients with subtypes HER2BC (P < 0.001) or TNBC (P = 0.011) and was significantly lower in patients with subtype HRBC (P < 0.001). The objective response and pCR rates were significantly higher in the high-TIL group than in the low-TIL density group (P = 0.031 and P < 0.001, respectively).

In the analysis of the 29 patients with post-operative recurrence, those with high, compared with low, TIL density in the primary tumour had a higher objective response rate (P = 0.022). However, there was no significant difference in objective response rate based on the density of TIL in recurrent tumours (Table 2). Moreover, no correlation was found between other clinicopathological features and TIL density in either primary or recurrent tumours.

TIL density in primary vs. recurrent tumours
TIL density was significantly lower in recurrent than in primary tumours (P = 0.007) (Fig. 2a), specifically in subtype HER2BC tumours (P = 0.029); all such tumours had low TIL density (Fig. 2b). Of subtype TNBC tumours, 63.6% (7/11) of primary vs. 18.2% (2/11) of recurrent tumours showed high TIL density (Fig. 2c); no significant difference was observed in recurrent tumours of subtype HRBC (P = 0.627) or TNBC (P = 0.109) (Fig. 2d).

Prognostic analysis using TIL density in primary and recurrent tumours
Of the 264 patients whose data were analysed, disease-free survival was significantly longer in the high-TIL group than in the low-TIL density group (P = 0.047) (Supplemental Fig. 2a). In particular, a significant difference was observed in patients with subtype HER2BC (P = 0.046) and TNBC (P = 0.028) tumours (Supplemental Fig. 2b, c); no significant difference was observed for subtype HRBC (P = 0.968) (Supplemental Fig. 2d). No significant differences in overall survival were demonstrated between patients with high vs. low TIL density overall or stratified by intrinsic subtype (Supplemental Fig. 3). Although there was no difference in PRS based in the level of TIL density in primary tumours (P = 0.83) (Fig. 3a), TIL density in recurrent tumours was

Table 1. Clinicopathological features of 264 patients who were treated with NAC and 29 postoperative-recurrence patients

| Parameters                        | Number of patients who treated with NAC (n=264) (%) | Number of postoperative-recurrence patients (n=29) (%) |
|-----------------------------------|---------------------------------------------------|------------------------------------------------------|
| Age (years old)                   | 55 (27–90)                                         | 53 (30–69)                                           |
| Tumour size (cm)                  | 2.9 (1.0–9.8)                                      | 2.6 (1.8–8.5)                                        |
| Lymph node status                 | 78 (29.5%) / 186 (70.5%)                           | 5 (17.2%) / 24 (82.8%)                               |
| Oestrogen receptor                | 138 (52.3%) / 126 (47.7%)                          | 19 (65.5%) / 10 (34.5%)                              |
| Progesterone receptor             | 179 (67.8%) / 85 (32.2%)                           | 20 (69.0%) / 9 (31.0%)                               |
| HER2 Negative/Positive            | 184 (69.7%) / 80 (30.3%)                           | 22 (75.9%) / 7 (24.1%)                               |
| Ki67 ≤14% / >14%                  | 87 (33.0%) / 177 (67.0%)                           | 13 (44.8%) / 16 (55.2%)                              |
| Intrinsic subtype                 | 129 (48.9%) / 53 (20.1%) / 82 (31.1%)              | 11 (37.9%) / 7 (24.1%) / 11 (37.9%)                   |
| Objective response rate           | 26 (9.8%) / 238 (90.2%)                            | 7 (24.1%) / 22 (75.9%)                               |
| Pathological complete response    | 173 (65.5%) / 91 (34.5%)                           | 22 (75.9%) / 7 (24.1%)                               |
| TILs Low/High                     | 140 (53.0%) / 124 (47.0)                           | 14 (48.3%) / 15 (51.7%)                              |

NAC neoadjuvant chemotherapy, HER human epidermal growth factor receptor, HRBC hormone receptor-positive breast cancer (ER+ and/or PgR+), HER2BC human epidermal growth factor receptor 2-enriched breast cancer (ER−, PgR−, and HER2+), TNBC triple negative breast cancer (ER−, PgR−, and HER2−), pCR pathological complete response
Table 2. Correlation between clinicopathological features and TILs in 29 primary and recurrent tumour

| Parameters                          | Primary tumour | Recurrent tumour |
|------------------------------------|----------------|-----------------|
|                                    | High TILs (n=15) | Low TILs (n=14) | P-value | High TILs (n=6) | Low TILs (n=23) | P-value |
| Age at recurrence (years old)      |                |                |         |                |                |         |
| ≤53                                | 7 (46.7%)      | 8 (57.1%)      | 0.589   | 2 (33.3%)      | 13 (56.5%)     | 0.329   |
| >53                                | 8 (53.3%)      | 6 (42.9%)      |         | 4 (66.7%)      | 10 (43.5%)     |         |
| Tumour size (cm)                   |                |                |         |                |                |         |
| ≤2.6                               | 7 (46.7%)      | 7 (50.0%)      | 0.864   | 2 (33.3%)      | 12 (52.2%)     | 0.429   |
| >2.6                               | 8 (53.3%)      | 7 (50.0%)      |         | 4 (66.7%)      | 11 (47.8%)     |         |
| Lymph node status                  |                |                |         |                |                |         |
| Negative                           | 2 (13.3%)      | 3 (21.4%)      | 0.5803  | 1 (16.7%)      | 4 (17.4%)      | 0.968   |
| Positive                           | 13 (86.7%)     | 11 (78.6%)     |         | 5 (83.3%)      | 19 (82.6%)     |         |
| Ki67                               |                |                |         |                |                |         |
| ≤14%                               | 8 (53.3%)      | 5 (35.7%)      | 0.358   | 1 (16.7%)      | 12 (52.2%)     | 0.128   |
| >14%                               | 7 (46.7%)      | 9 (64.3%)      |         | 5 (83.3%)      | 11 (47.8%)     |         |
| Intrinsic subtype HRBC             |                |                |         |                |                |         |
| Non-HRBC                           | 11 (73.3%)     | 7 (50.0%)      | 0.209   | 2 (33.3%)      | 16 (69.6%)     | 0.111   |
| HRBC                               | 4 (26.7%)      | 7 (50.0%)      |         | 4 (66.7%)      | 7 (30.4%)      |         |
| Intrinsic subtype HER2BC           |                |                |         |                |                |         |
| Non-HER2BC                         | 11 (73.3%)     | 11 (78.6%)     | 0.753   | 6 (100%)       | 16 (69.6%)     | 0.130   |
| HER2BC                             | 4 (26.7%)      | 3 (21.4%)      |         | 0 (0%)         | 7 (30.4%)      |         |
| Intrinsic subtype TNBC             |                |                |         |                |                |         |
| Non-TNBC                           | 8 (53.3%)      | 10 (71.4%)     | 0.333   | 4 (66.7%)      | 14 (60.9%)     | 0.803   |
| TNBC                               | 7 (46.7%)      | 4 (28.6%)      |         | 2 (33.3%)      | 9 (39.1%)      |         |
| Objective response rate            |                |                |         |                |                |         |
| Non-responders                     | 1 (6.7%)       | 6 (42.9%)      | 0.022   | 2 (33.3%)      | 5 (21.7%)      |         |
| Responder                          | 14 (93.3%)     | 8 (57.1%)      |         | 4 (66.7%)      | 18 (78.3%)     | 0.571   |
| Pathological complete response     |                |                |         |                |                |         |
| Non-pCR                            | 10 (66.7%)     | 12 (85.7%)     | 0.246   | 6 (100%)       | 16 (69.6%)     | 0.130   |
| pCR                                | 5 (33.3%)      | 2 (14.3%)      |         | 0 (0%)         | 7 (30.4%)      |         |
| Hormone therapy after surgery      |                |                |         |                |                |         |
| No                                 | 8 (53.3%)      | 9 (64.3%)      | 0.566   | 2 (33.3%)      | 15 (65.2%)     | 0.169   |
| Yes                                | 7 (46.7%)      | 5 (35.7%)      |         | 4 (66.7%)      | 8 (34.8%)      |         |
| Radiation therapy after surgery    |                |                |         |                |                |         |
| No                                 | 8 (53.3%)      | 7 (50.0%)      | 0.864   | 5 (83.3%)      | 10 (43.5%)     | 0.087   |
| Yes                                | 7 (46.7%)      | 7 (50.0%)      |         | 1 (16.7%)      | 13 (56.5%)     |         |
| Trastuzumab after surgery          |                |                |         |                |                |         |
| No                                 | 10 (66.7%)     | 12 (85.7%)     | 0.246   | 6 (100%)       | 16 (69.6%)     | 0.130   |
| Yes                                | 5 (33.3%)      | 2 (14.3%)      |         | 0 (0%)         | 7 (30.4%)      |         |
| No-treatment after surgery         |                |                |         |                |                |         |
| No                                 | 13 (86.7%)     | 11 (78.6%)     | 0.580   | 4 (66.7%)      | 20 (87.0%)     | 0.257   |
| Yes                                | 2 (13.3%)      | 3 (21.4%)      |         | 2 (33.3%)      | 3 (13.0%)      |         |
| Disease-free survival (weeks)      |                |                |         |                |                |         |
| ≤65                                | 7 (46.7%)      | 7 (50.0%)      | 0.864   | 4 (66.7%)      | 10 (43.5%)     | 0.329   |
| >65                                | 8 (53.3%)      | 7 (50.0%)      |         | 2 (33.3%)      | 13 (56.5%)     |         |
| Recurrent tumour site              |                |                |         |                |                |         |
| Locoregional                       | 8 (53.3%)      | 10 (71.4%)     | 0.333   | 5 (83.3%)      | 13 (56.5%)     | 0.243   |
| Other                              | 7 (46.7%)      | 4 (28.6%)      |         | 1 (16.7%)      | 10 (43.5%)     |         |
| TILs of recurrent tumour           |                |                |         |                |                |         |
| Low                                | 13 (86.7%)     | 10 (71.4%)     | 0.329   | –              | –             |         |
| High                               | 2 (13.3%)      | 4 (28.6%)      |         | –              | –             |         |

TILs, tumour infiltrating lymphocytes; HRBC, hormone receptor positive breast cancer; HER2BC, human epidermal growth factor receptor 2-enriched breast cancer; TNBC, triple negative breast cancer; ORR, overall response rate; pCR, pathological complete response.
significantly associated with PRS. The PRS of patients whose specimens demonstrated high TIL density was significantly better than of those demonstrating low TIL density \( P = 0.041 \) (Fig. 3b). In the subtype analysis, the level of TIL density in recurrent tumours was not associated with PRS (HER2BC: unable to calculate, TNBC: \( P = 0.255 \), HRBC: \( P = 0.063 \)) (Supplemental Figure 4a-c). Progression-free survival was not associated with the level of TIL density overall \( P = 0.244 \) or for any of the subtypes (HER2BC: unable to calculate, TNBC: \( P = 0.273 \), HRBC: \( P = 0.054 \)) (Supplemental Figure 5a-d). On univariate analysis, high TIL density was significantly associated with improved PRS in all patients \( P = 0.035 \), HR = 0.167 \) (Table 3).

**DISCUSSION**

The subtype of recurrent breast cancer may differ from that of the primary cancer. Because this may influence subsequent treatment, re-evaluation at the time of recurrence is necessary. In a study by Dieci et al., subtype changes occurred in 22.7% of cases. PRS was significantly poorer for patients with discordant subtypes than for patients with concordant subtypes.\(^2\) Furthermore, in one-third of the discordant group, the subtype transformed to TNBC; PRS was poorer in all these cases. In a study by Liedtke et al., the PRS of patients with discordant TNBC was significantly worse than that of patients with concordant TNBC.\(^3\) In the current study, two cases of HRBC transformed to TNBC: one from HER2BC to HRBC, and one from HRBC to HER2BC. Thus, discordance was observed in 13.8% of cases—half of which transformed to TNBC; there was no difference in prognosis owing to these subtype changes. There was no significant difference between subtypes.\(^1\), \(^4\) When there were significant differences in PRS among subtypes, more than half of the patients had distant disease recurrence. This could be because TNBC is frequently associated with visceral metastasis, which has a poorer prognosis than local recurrence.\(^20,\) \(^21\) Furthermore, because patients with discordant TNBC had significantly worse PRS than did patients with concordant TNBC, appropriate treatment that considered the change in subtype was probably not implemented. When biopsy was performed earlier for recurrence, as was done in this study, treatment was effective owing to early detection of the subtype change, thereby increasing the probability of choosing the most appropriate treatment modality.

In this study, no difference in PRS was observed, irrespective of biomarker expression in primary or recurrent tumours. However, PRS was reported to be better in ER-positive than in ER-negative breast cancer.\(^22\) The brain and lungs are also recognised as sites of HER2BC and TNBC recurrence; the fact that recurrent lesions in the brain and lung are only diagnosed on imaging may affect these findings. Moreover, PRS is better for patients with breast cancer, with a longer time to recurrence.\(^20\) This is probably due to slow proliferation caused by the low malignant potential and proliferative capacity of primary breast cancer cells, with recurrent

---

**Fig. 2**  TIL density was significantly lower in recurrent than in primary breast cancers (a). There was a significant decrease in TIL density in HER2BC tumours; all recurrent HER2BC tumours demonstrated low TIL density (b). No significant change in TIL density was observed in HRBC (c) and TNBC tumours (d). TIL tumour-infiltrating lymphocyte, HER2BC HER2-enriched breast cancer, HRBC hormone receptor-positive breast cancer, TNBC triple-negative breast cancer.
foci manifesting over a long period. However, no significant differences were observed; further examination of a larger population would be beneficial.

In recent years, the TME has attracted attention as a therapeutic target, and TIL density has been shown to be a useful index for monitoring cancer. TIL density varies depending on cancer subtype. However, many studies examined only pre-treatment specimens, and HER2BC and TNBC are known to express higher levels of TIL than HRBC does. In the present study, the correlation between clinicopathological features and TIL density in recurrent tumours. TIL density also in environments in patients who underwent surgery after neoadjuvant chemotherapy led to high objective response and pCR rates. As described previously, TIL density is often high in subtypes HER2BC and TNBC, these high tumour immune responses contribute to more favourable disease-free and overall survival rates. In the present study, good immune environments in patients who underwent surgery after neoadjuvant chemotherapy led to high objective response and pCR rates. Patients with HER2BC or TNBC with high TIL density had significantly longer disease-free survival durations than did comparative patients with low TIL density. Thus, overall, patients with high TIL density had longer disease-free survival.

The study findings also demonstrate that the immune milieu in the TME of recurrent tumours affects prognosis after relapse. The decrease in TIL density in recurrent tumours indicates immune escape; this contributes to lowering the therapeutic effect. In

Thus, although no differences in PRS were reported in most subgroup analyses, there was a significant difference in PRS based on TIL density in recurrent tumours. TIL density also influences therapeutic effects after recurrence. Although the number of participants was very small to evaluate PRS for each subtype, a significant decrease in TIL density was observed in recurrent HER2BC; all of these patients demonstrated low TIL density. At the time of recurrence, TIL density was lower not only in subtype HER2BC but also in subtype TNBC. As described previously, TIL density is often high in subtypes HER2BC and TNBC; these high tumour immune responses contribute to more favourable disease-free and overall survival rates. In the present study, good immune environments in patients who underwent surgery after neoadjuvant chemotherapy led to high objective response and pCR rates. Patients with HER2BC or TNBC with high TIL density had significantly longer disease-free survival durations than did comparative patients with low TIL density. Thus, overall, patients with high TIL density had longer disease-free survival.

The study findings also demonstrate that the immune milieu in the TME of recurrent tumours affects prognosis after relapse. The decrease in TIL density in recurrent tumours indicates immune escape; this contributes to lowering the therapeutic effect. In

Kaplan–Meier curves stratified by TIL density in primary and recurrent tumours. Post-recurrence survival was similar between patients with high vs. low TIL density in the primary tumour (a), but was significantly longer in patients with high (vs. low) TIL density in the recurrent tumour (b). TIL tumour-infiltrating lymphocyte

**Table 3.** Univariate and multivariate analysis with post-recurrence survival

| Parameters                               | Univariate analysis | Multivariate analysis |
|------------------------------------------|---------------------|-----------------------|
|                                          | Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value |
| Age at recurrence (years old) ≤53 vs. >53 | 0.874      | 0.279–2.651  | 0.811  |
| Primary tumour size (cm) ≤2.6 vs. >2.6  | 1.510      | 0.471–4.632  | 0.476  |
| Lymph node status Negative vs. Positive | 0.285      | 0.074–1.370  | 0.108  |
| Ki67 ≤14% vs. >14%                      | 0.518      | 0.158–1.515  | 0.232  |
| Intrinsic subtype HRBC No vs. Yes       | 0.549      | 0.150–1.649  | 0.295  |
| Intrinsic subtype HER2BC No vs. Yes     | 1.118      | 0.341–3.265  | 0.843  |
| Intrinsic subtype TNBC No vs. Yes       | 1.736      | 0.520–5.254  | 0.350  |
| Objective response rate Responder vs. Non-responders | 0.554  | 0.179–2.053  | 0.350  |
| Pathological complete response pCR vs. Non-pCR | 1.589  | 0.354–5.257  | 0.504  |
| Hormone therapy after surgery No vs. Yes | 0.599      | 0.183–1.742  | 0.351  |
| Radiation therapy after surgery No vs. Yes | 1.066      | 0.364–3.121  | 0.906  |
| Trastuzumab after surgery No vs. Yes     | 0.908      | 0.2468–2.743 | 0.870  |
| No-treatment after surgery No vs. Yes    | 2.049      | 0.456–6.773  | 0.312  |
| Disease-free survival (weeks) ≤65 vs. >65 | 2.714      | 0.828–12.127 | 0.103  | 2.475      | 0.735–11.227 | 0.150  |
| Recurrent tumour site Locoregional vs. Other | 1.267      | 0.384–5.684  | 0.716  |
| TILs of recurrent tumour Low vs. High    | 0.154      | 0.008–0.794  | 0.021  | 0.167      | 0.009–0.900  | 0.035  |

TILs tumour infiltrating lymphocytes, HRBC hormone receptor positive breast cancer, HER2BC human epidermal growth factor receptor 2-enriched breast cancer, TNBC triple negative breast cancer, ORR overall response rate, pCR pathological complete response, CI confidence intervals
particular, for patients with HER2BC treated with trastuzumab, immune escape is a factor in recurrence because of the incomplete antibody activity of dependent cellular cytotoxicity. The poor immune milieu in the TME of recurrent tumours could be as a cause of malignancy in HER2BC, indicating that the immune TME is an important contributor to therapeutic effects in recurrence.

There are known differences in the TIL subset between primary breast cancer and distant metastasis or recurrent lesions. Ogiya et al. reported no changes in FOXP3+ T-cells, but significantly decreased CD8+ and CD4+ T-cells. It is speculated that immune escape occurs with decreases in both the concentrations of CD8+ T-cells (which suppress cancer proliferation) and lymphocytes (which promote cancer proliferation); this may imply an overall decrease in the functioning of the immune system. In these reports, the rates of cancer suppression and promotion were evaluated in lymphocytes. Analysis of TIL subsets and the proportions thereof might be more sensitive as a biomarker. In addition, TILs can be evaluated from any biopsy specimen, irrespective of recurrence, to predict outcomes such as PRS.

In this study, PRS was significantly associated with the level of TIL density in recurrent tumours. Adherence, modification, and proliferation of cancer cells released from cancerous tissues during surgery could trigger recurrence because immune escape is an important factor in tumour progression. Therefore, for patients with recurrent tumours, TIL density could be a biomarker for PRS. A limitation of this study is the small sample size; therefore, it is necessary to conduct further studies to examine subgroup characteristics in a greater number of patients.

In recurrent BC, a decrease in TILs density was observed for recurrent tumours as compared to primary tumours. Furthermore, TILs density in recurrence had an influence on the prognosis after relapse. TILs is also important for post-recurrence therapy, and the possibility that improved TILs density may lead to a better prognosis for relapse patients could also be inferred.

ACKNOWLEDGEMENTS

We thank Wakaba Fukushima (Department of Public Health, Osaka City University Graduate School of Medicine) for statistical analysis. And, we thank Yayo Matsuiyo and Tomomi Okawa (Department of Surgical Oncology, Osaka City University Graduate School of Medicine) for their helpful advice regarding data management. This study was supported in part by Grants-in-Aid for Scientific Research (KAKENHI, Nos. 25461992, 26461957 and 17K10559) from the Ministry of Education, Science, Sports, Culture and Technology of Japan.

AUTHOR CONTRIBUTIONS

All authors were involved in the preparation of this manuscript. K Takada collected the data, and wrote the manuscript. S.K., W.G., Y.A., K.Takahashi, T.H., and T.T. performed the operation and designed the study. K.Takada, S.K., and S.T. summarised the data, and wrote the manuscript. S.K., W.G., Y.A., K.Takahashi, T.H., and T.T. were involved in the preparation of this manuscript. K.Takada collected the data, and revised the manuscript. All authors read and approved the final manuscript.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at https://doi.org/10.1038/s41416-018-0197-4.

Availability of data and material: The data and materials used and analyzed in the current study are available from the corresponding author on request.

Ethics approval and consent to participate: Written informed consent was obtained from all subjects. This research conformed to the provisions of the Declaration of Helsinki in 2013. All patients were informed of the investigational nature of this study and provided their written, informed consent. The study protocol was approved by the Ethics Committee of Osaka City University (#926).

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

REFERENCES

1. Amir, E. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 30, 587–592 (2012).
2. Dieci, M. V. et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann. Oncol. 24, 101–108 (2013).
3. Lidtke, C. et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann. Oncol. 20, 1953–1958 (2009).
4. Nishimura, R. et al. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J. Surg. Oncol. 9, 131 (2011).
5. Adams, S. et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32, 2959–2966 (2014).
6. Denkert, C. et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 33, 983–991 (2015).
7. Asano, Y. et al. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br. J. Cancer 114, 14–20 (2016).
8. Greene, F. L. & Sobin, L. H. A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J. Surg. Oncol. 99, 269–272 (2009).
9. Goldhirsch, A. et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22, 1736–1747 (2011).
10. Kawajiri, H. et al. Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer. Oncol. Lett. 4, 612–616 (2012).
11. Mauri, D., Pavlidis, N. & Ioannidis, J. P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl. Cancer Inst. 97, 188–194 (2005).
12. Mieog, J. S., van der Hage, J. A. & van de Velde, C. J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst. Rev. 2, CD000502 (2007).
13. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
14. Kashiwagi, S. et al. Partial mastectomy using manual blunt dissection (MBD) in early breast cancer. BMC Surg. 15, 117 (2015).
15. Wolmark, N., Wang, J., Mamounas, E., Bryant, J. & Fisher, B. Preoperative chemotherapy in women with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 30, 96–102 (2001).
16. McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 23, 9067–9072 (2005).
17. Kashiwagi, S. et al. Use of tumor-infiltrating lymphocytes (TILs) to predict the treatment response to erbulin chemotherapy in breast cancer. PLoS ONE 12, e0170634 (2017).
18. Mao, Y. et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS ONE 9, e115103 (2014).
19. Ono, M. et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 132, 793–805 (2012).
20. Blanco, G., Holl, K., Heikkinen, M., Kallioniemi, O. P. & Taskinen, P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br. J. Cancer 62, 142–146 (1990).
21. Park, S. et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. *Breast* 21, 50–57 (2012).

22. Kennecke, H. et al. Metastatic behavior of breast cancer subtypes. *J. Clin. Oncol.* 28, 3271–3277 (2010).

23. Asano, Y. et al. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. *Br. J. Surg.* 103, 845–854 (2016).

24. Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann. Oncol.* 26, 259–271 (2015).

25. Savas, P. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. *Nat. Rev. Clin. Oncol.* 13, 228–241 (2016).

26. Ohtani, H., Mori-Shiraishi, K., Nakajima, M. & Ueki, H. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. *Pathol. Int.* 65, 644–651 (2015).

27. Stanton, S. E., Adams, S. & Disis, M. L. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. *JAMA Oncol.* 2, 1354–1360 (2016).

28. Sobottka, B., Pestalozzi, B., Fink, D., Moch, H. & Varga, Z. Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. *Oncoimmunology* 5, e1153208 (2016).

29. Cimino-Mathews, A., Ye, X., Meeker, A., Argani, P. & Emens, L. A. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. *Hum. Pathol.* 44, 2055–2063 (2013).

30. Ogiya, R. et al. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. *Cancer Sci.* 107, 1730–1735 (2016).